MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with an initial focus on industrial safety applications in South America’s mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.
Leyton brings extensive experience in national drug policy and workplace safety, having helped design and implement Chile’s ‘Zero Tolerance’ alcohol-impaired driving law as part of the country’s alcohol prevention framework. He also played a role in establishing Chile’s roadside drug testing program introduced in 2019. His appointment reflects MindBio’s strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
MindBio’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication in a range of enterprise environments including the mining industry, aviation, construction, and law enforcement.
The move toward commercial deployment in South America’s mining sector is significant because the region has high rates of workplace accidents linked to substance impairment. Mining companies face strict safety regulations and are increasingly seeking non-invasive, rapid screening technologies. MindBio’s voice-based solution offers a potential advantage over traditional methods such as breathalyzers or saliva tests, which can be intrusive and time-consuming.
According to the company, the AI solution can detect impairment in seconds by analyzing vocal biomarkers, providing a scalable tool for employers to enhance workplace safety. The platform is designed to be integrated into existing security checkpoints or used as standalone kiosks at mine entrances. With Leyton’s regulatory expertise, MindBio aims to navigate local compliance frameworks and build partnerships with mining operators.
For further details, the full article is available at https://ibn.fm/JBNVq. More information about MindBio Therapeutics is available in the company’s newsroom at https://ibn.fm/MBQIF.
